You should report signs of bleeding or infections to your health care provider. It is important to be compliant with blood cell count monitoring appointments while receiving Xofigo. Male patients should use condoms and their female partners (of reproductive potential) should use effective contraception during and for 6 months after completing treatment with Xofigo.īased on how Xofigo works it may impair a male's ability to father children if they are of reproductive potential. Male patients should not get female partners pregnant during treatment with Xofigo and for 6 months after stopping treatment. It is important to warn pregnant females and females of reproductive potential of the potential risk to a fetus. Xofigo can cause fetal harm when administered to a pregnant female. The safety and efficacy of Xofigo have not been established in females. This medicine should be discontinued in patients who experience life-threatening complications despite supportive care measures. Monitor patients with compromised bone marrow reserve closely. Discontinue Xofigo if hematologic values do not recover within 6 to 8 weeks after treatment. Warningsīone Marrow Suppression: Blood counts should be measured before the first treatment and also before every dose of Xofigo. Once Xofigo is attached to the bone cancer, it gives off radiation that breaks the DNA of the cancer cells, which kills the prostate cancer cells. Xofigo works as it acts like calcium and goes to areas of bone that are growing quickly, which is where the bone cancer is in the body. Xofigo contains a radioactive ingredient called radium 233 that concentrates in the bone where there is cancer and kills the cancer cells. Xofigo (radium 223 dichloride) is an intravenous injection used for the treatment of prostate cancer when hormonal or surgical treatment that lowers testosterone is no longer working, and the prostate cancer has spread to bones but has not spread to other parts of the body. Medically reviewed by Melisa Puckey, BPharm. You are encouraged to report side effects or quality complaints of products to the FDA by visiting or call 1‑800‑FDA‑1088.Drug class: Therapeutic radiopharmaceuticals
#RADIUM 223 FULL#
Tell your healthcare provider if you have any side effects that bother you or do not go away.įor important risk and use information about Xofigo, please see the Full Prescribing Information. swelling of the arms or legs (peripheral edema).The most common side effects of Xofigo include: follow good hygiene practices in order to minimize radiation exposure from spills of bodily fluids to household members and caregivers for a period of one week after each injection.people who are handling fluids such as urine, feces, or vomit of a man taking Xofigo should wear gloves and wash their hands as precaution.there are no restrictions regarding personal contact (visual or physical proximity) with other people after receiving Xofigo.stay well hydrated and report any signs of dehydration (such as dry mouth and increased thirst), or urinary or kidney problems (such as burning when urinating).Report symptoms or signs of shortness of breath, tiredness, bleeding (such as bruising), or infection (such as fever) make sure you keep your blood cell count monitoring appointments and tell your healthcare provider about any symptoms or signs of low blood cell counts.are taking Zytiga ® (also known as abiraterone) with prednisone/prednisolone, as this may increase the risk of bone fractures (breaks) and death.are receiving any chemotherapy or another extensive radiation therapy.Your healthcare provider will do blood tests before and during treatment with Xofigo In addition, there were some deaths and blood transfusions that occurred due to severe bone marrow problems. In a clinical trial, some patients had to permanently discontinue therapy because of bone marrow problems. Xofigo can cause your blood cells counts to go down, including red blood cells, white blood cells, and/or platelets. Before taking Xofigo, tell your healthcare provider if you: Men should use condoms and make sure female partners who may become pregnant use birth control (contraception) during treatment and for 6 months after completing treatment with Xofigo. Xofigo can harm unborn babies when given to a pregnant woman. It is not known if Xofigo is safe and effective in women. It is for men whose prostate cancer has spread to the bone with symptoms but not to other parts of the body. Xofigo ® (radium Ra 223 dichloride) injection is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone.
0 kommentar(er)
